The two studies review the safety and effectiveness of recombinant human bone morphogenic protein-2 for spinal fusion, finding low degrees of efficacy and higher rates of adverse effects than were originally reported in industry-sponsored studies. Some of the adverse events relate to cancer.
“A surgeon would need a truly exceptional case to use BMP-2 when data supporting its use are marginal and the scant complications data we have comes through potentially biased filters at every level,” wrote Dr. Carragee in the statement. “If complications monitoring processes were as biased as the analyses and reporting process have proven to be, then data YODA was given fundamentally and systematically misrepresent the risk of BMP-2 use.”
In 2011, The Spine Journal published a special edition with data and commentary about risks and potential for bone morphogenic protein. In this statement, Dr. Carragee further calls for examining the financial relationship between physician researchers and device companies.
The North American Spine Society has releases a response as well.
More Articles on Spine Surgeons:
26 Awarded 2013 Scoliosis Research Society Awards and Scholarships
Reoperation for Spinal Fusion vs. Disc Replacement: 5 Things to Know
8 Defining Issues for Spine Surgeons Today
At the Becker's 23rd Annual Spine, Orthopedic and Pain Management-Driven ASC + The Future of Spine Conference, taking place June 11-13 in Chicago, spine surgeons, orthopedic leaders and ASC executives will come together to explore minimally invasive techniques, ASC growth strategies and innovations shaping the future of outpatient spine care. Apply for complimentary registration now.
